Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

Top of the class: Rhythm’s latest study results outperform the standard

  • In News
  • May 6, 2021
  • Samantha Freidin
Top of the class: Rhythm’s latest study results outperform the standard

Colorectal cancer is the third most commonly occurring cancer in men, and the second in women. Yet every year 130 million people around the world between the ages of 50-74 remain unscreened.

Rhythm Biosciences (ASX: RHY) are not complacent with that number and are working on an innovative solution to aid diagnosis of this major health problem.

Recognising the issue, public health authorities have long been urging Australian’s to get tested for colorectal cancer. Under the National Bowel Cancer Screening Program, Australian’s aged between 50 and 74 receive a free home screening kit in the mail every two years. The 2018-19 federal budget allowed for $35 million over four years to fund the recall of people who received a positive test result but have not attended their GP to follow up.

The current market standard diagnostic test for colorectal cancer is the faecal immunochemical test (FIT). Rhythm’s offering, ColoSTAT® is a simple blood test that offers higher accuracy than the FIT, at a lower cost.

Rhythm recently announced study results showing that ColoSTAT® was able to perform with an accuracy of 84%, outperforming the current market standard.

The Company is further expanding their testing functionality with their algorithm now able to take into account Lifestyle Related Factors (LRFs) such as diet, weight, exercise and smoking status. These factors are proven to affect the incidence and mortality of the cancer. The addition of LRFs has demonstrated an increased testing accuracy of 5%. Further studies are being carried out to determine if the LRF enhancement will be integrated with Rhythm’s core cancer detection technology for the final testing product.

Their proprietary algorithm and AI framework allows for ColoSTAT® to be easily used in labs and eliminates the need for additional operator training and additional infrastructure, thereby reducing the cost of screening. The AI framework learns as the database of results grows which offers the potential for further performance improvement in the future.

By increasing screening rates, the Company hopes to help reduce morbidity and mortality rates and lower the costs associated with colorectal cancer.

There clearly is a demand for a better solution and with market potential of over $6.5 billion, Rhythm is well positioned to tap in.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • cancer screening
  • colorectal cancer
  • colostat
  • diagnostics
  • lrf
  • medtech
  • rectal cancer
  • rhy
  • rhythm biosciences
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.